The U.S. Chamber of Commerce’s (Global Intellectual Property Center) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests USTR classify India as a Priority Foreign Country specifically citing concerns over compulsory licensing. The submission noted that India… Continue Reading
PhRMA’s submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests USTR classify India as a Priority Foreign Country citing the fact that India “continues to embrace these damaging policies, especially its IP rules, by publicly highlighting them… Continue Reading
The National Foreign Trade Council (NFTC) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requested USTR to designate India as a Priority Foreign Country and “conduct an out-of-cycle review of India to assess” Indian policies “across sectors,… Continue Reading
The National Association of Manufacturers’s (NAM) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests that USTR designate India as a Priority Foreign Country citing concerns with India’s actions in multilateral fora including the UNFCCC, WTO and… Continue Reading
The Intellectual Property Owners Association’s (IPO) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review expressed concern over various aspects of India’s policies including “India’s Forced Technology Transfer, Compulsory Licensing, and Lack of Effective IP Protection” and “Third… Continue Reading
The Biotechnology Industry Organization (BIO) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requested USTR to designate India a Priority Foreign Country. BIO expressed concerns over the robust use of patent oppositions in India: The Indian generic… Continue Reading
A February 7, 2014 Special 301 submission from the National Foreign Trade Council (NFTC) asks USTR to bring trade sanctions against China for granting and enforcing “junk patents.” The NFTC also wants patent enforcement to be strickly a private civil remedy (Contrast to the USTR demands that countries implement linkage between drug registration and patents), and complains about China rules that would require employers to more fairly compensation the Chinese inventors they Continue Reading
Attached in the February 7, 2014, KEI Special 301 Submission.
KEI was a web page with more context on the Special 301 reports, including links to several submissions, and all Special 301 Reports from 1989 to 2013 (all that exist), here: /ustr/special301 Continue Reading
On January 21, 2014, Ketaki Gokhale of Bloomberg published a story in Businessweek on disputes over drug patents. The story closed with a rather sinister quote attributed to Bayer CEO Marijn Dekkers, “We did not develop this medicine for Indians. Continue Reading
Next week, the United States International Trade Commission (ITC) will hold a two-day hearing on “Trade, Investment, and Industrial Policies in India: Effects on the US Economy.” The first session will take place Wednesday, February 12, 2014 at 1:00pm and the second session will convene on Thursday, February 13, 2014 at 9:30am. Both sessions will be held at the ITC in the Main Hearing Room (room 101) at 500 E Street SW, Washington, DC.